Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
Swiss-based Roche plans to exit four manufacturing sites globally. Workforce reduction is imminent.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.